Study guide
13.3 Submissions, Authorisation Status and Trial Reporting
ACRP CCRA Certified Clinical Research Associate Study Guide 2026 Exam
Track your progress as you read
Finished sections get a check mark.
1 Chapter 1: Exam Format, Eligibility and Registration
1.1 Exam Format, Eligibility and Current References 1.2 Registration, Fees and Candidate Decisions
2 Chapter 2: CRA Responsibilities and Study Planning
2.1 The CRA Role, Data Integrity and Product Oversight 2.2 Official Blueprint and Study Strategy
3 Chapter 3: Protocols, Endpoints and Trial Design
3.1 Protocol Elements and Endpoint Hierarchy 3.2 Endpoint Interpretation and Eligibility Rationale 3.3 Eligibility Verification and Trial Designs
4 Chapter 4: Bias Control, Blinding and Product Information
4.1 Bias, Randomisation and Comparator Controls 4.2 Unblinding and Investigator Brochure Content 4.3 Reference Safety Information and IB Updates
5 Chapter 5: Estimands and Device Instructions
5.1 Estimands and Intercurrent Events 5.2 Device Instructions, Configuration and Training
6 Chapter 6: Ethical Foundations and Independent Oversight
6.1 Ethical Foundations and the 2024 Declaration of Helsinki 6.2 Vulnerability, Voluntariness and Compensation 6.3 IRB/IEC Composition and Independent Review
7 Chapter 7: Ethics Communication and Informed Consent
7.1 Ethics Reporting, Approval Status and Version Control 7.2 Informed Consent Information and Meaningful Choice 7.3 Consent Documentation, Special Circumstances and Updates
8 Chapter 8: Recruitment, Retention and Confidentiality
8.1 Ethical Eligibility, Recruitment and Retention 8.2 Privacy, Confidentiality and Appropriate Access
9 Chapter 9: Safety Definitions and Classification
9.1 Adverse Event Definitions and Actual Life-Threatening Risk 9.2 Seriousness, Severity and Medical Importance 9.3 Causality, Expectedness and Reference Safety Information
10 Chapter 10: Safety Detection, Reporting and Oversight
10.1 Detecting Events, AESIs and Collection Windows 10.2 Expedited Reporting and the Sponsor Awareness Clock 10.3 Immediate Site Reporting and Independent Safety Oversight
11 Chapter 11: Follow-Up, Adherence and Conflicts
11.1 Safety Communications, Reconciliation and Follow-Up 11.2 Adherence, Discontinuation and Participant Choice 11.3 Conflicts of Interest and Prorated Payments
12 Chapter 12: Development Stages and Product Management
12.1 Nonclinical Background and Human Pharmacology 12.2 Exploratory, Confirmatory and Therapeutic-Use Studies 12.3 Product Storage, Labelling and Excursion Response
13 Chapter 13: Accountability, Integrity and Regulatory Status
13.1 Product Accountability and Adherence Calculations 13.2 Potential Fraud, Misconduct and Evidence Preservation 13.3 Submissions, Authorisation Status and Trial Reporting
14 Chapter 14: Current GCP Principles and Delegation
14.1 The Eleven Current GCP Principles 14.2 Proportionality and Investigator Oversight 14.3 Delegation, Qualifications and Task Authority
15 Chapter 15: Oversight, Protocol Control and Amendments
15.1 Clinical Oversight and Immediate-Hazard Changes 15.2 Deviation Classification and Resolution
16 Chapter 16: Implementation and Trial Responsibilities
16.1 Amendment Implementation and Communication 16.2 Sponsor, Investigator and Service-Provider Roles
17 Chapter 17: Quality Planning, Root Causes and CAPA
17.1 Quality Planning and Risk Management 17.2 Root Cause Analysis and CAPA Design 17.3 CAPA Implementation and Effectiveness Verification
18 Chapter 18: Risk Assessment and Monitoring Methods
18.1 Risk Assessment and Centralised Surveillance 18.2 Monitoring Methods and Source Review
19 Chapter 19: Quality Metrics, Plans and Communication
19.1 KRIs, Acceptable Ranges and Trial-Level Quality 19.2 Monitoring Plans, Co-Monitoring and Communication
20 Chapter 20: Site Qualification and Readiness
20.1 Site Qualification and Investigator Capacity 20.2 Recruitment Feasibility and Evidence-Based Site Selection 20.3 Site Readiness and Activity-Specific Release
21 Chapter 21: Initiation, Equipment and Supplies
21.1 Initiation Training and Readiness Walkthroughs 21.2 Equipment, Maintenance and Study Supplies
22 Chapter 22: Samples, Diagnostics and Financial Feasibility
22.1 Specimens, Diagnostic Results and Rater Quality 22.2 Contracts, Budgets and Operational Feasibility
23 Chapter 23: Interim Monitoring and Reporting
23.1 Interim Visit Preparation and Consent Review 23.2 Monitoring Eligibility, Safety and Products 23.3 Investigator Debrief and Monitoring Reports
24 Chapter 24: Essential Records, Audits and Findings
24.1 Essential Records and Site/Sponsor Reconciliation 24.2 Version History, Resolution Evidence and Noncompliance 24.3 Audits, Inspections and Closure Planning
25 Chapter 25: Close-Out, Retention and Destruction
25.1 Close-Out, Archiving and Continuing Obligations 25.2 Retention, Destruction and Long-Term Access
26 Chapter 26: Source Records and Good Documentation
26.1 Source Records and Foundational ALCOA Principles 26.2 Good Documentation, Completeness and Corrections 26.3 Source Access, Certified Copies and Context
27 Chapter 27: Electronic Systems, Metadata and Queries
27.1 EDC Design and Fit-for-Purpose Systems 27.2 Audit Trails, Electronic Outcomes and Device Choice 27.3 Queries, Coding and Supported Clinical Meaning
28 Chapter 28: Dataset Finalisation and Critical Data
28.1 Safety Reconciliation and Dataset Finalisation 28.2 Critical Data, Acquisition Tools and Interim Findings
13.3 Submissions, Authorisation Status and Trial Reporting
Key Takeaways Explain This Topic AI
Submission, receipt, review and approval are distinct states.
Authorisation can have version, site, population or activity limits.
Completion reports and transparency depend on accurate records and applicable responsibilities.
Last updated: October 2026
Submissions, Authorisation Status and Trial Reporting
The Regulatory Requirements domain covers communication with IRBs/IECs and authorities, protocol amendments and reporting such as safety and clinical study reports. ACRP explicitly limits its examination references to the listed ICH guidelines and Declaration of Helsinki. Learn how a CRA verifies appropriate authorisation and reporting without turning country-specific applications, form boxes or portal timelines into universal exam rules.
Before relevant trial activities begin, the responsible party makes the required submissions or notifications and obtains the necessary approval or authorisation under the applicable framework. Responsibilities differ by region: E6(R3) notes that sponsor or investigator/institution may make submissions, and ethics and authority processes may be combined. The monitoring task is to establish who is responsible and what evidence demonstrates that the activity is permitted.
Submission, receipt and approval are different states
A submission receipt confirms delivery; it does not necessarily establish acceptance, a favourable ethics opinion or authority permission. A request for changes can leave conditions outstanding. A final approval can be limited to a particular protocol version, site, population or activity. Read the decision and its conditions rather than treating any letter from a regulator as a green light.
- State What it establishes What still needs verification
- Prepared Documents exist for intended submission Completeness, review and actual transmission
- Submitted Material was sent through the required route Receipt, questions and applicable next steps
- Under review The responsible body is assessing it Permission to begin has not necessarily been granted
- Approved/authorised A decision permits specified activities Scope, versions, conditions and effective status
Suspended/withdrawn Previous permission has changed Participant protection, notifications and resumption conditions
A tracker should distinguish these states, identify the responsible person and link to actual evidence. It should not replace the underlying decision. A spreadsheet saying approved can be wrong; the source letter may cover an older consent version or contain an unresolved condition.
The submitted package and the site reality
Relevant scientific and operational information can include the protocol, product information, participant materials, qualifications and other documentation required by the reviewing body. The content depends on the activity and framework. The CRA verifies the correct trial, investigator/site, document identities and versions and follows up discrepancies through the authorised sponsor/site process.
Suppose a protocol amendment was submitted globally, but one site's local ethics decision is pending. The global submission does not by itself authorise the site to implement new research procedures. Confirm the required local status and approved transition plan. If an urgent change is needed to eliminate an immediate hazard, protect participants and promptly document/communicate the action rather than waiting for routine administrative processing.
Reporting during the trial
Safety information, changes affecting risk or conduct, relevant noncompliance and trial status can require communication. Use the applicable reporting framework and trial plan for responsibility, recipient, content and timing. Distinguish investigator-to-sponsor immediate SAE reporting from sponsor expedited authority reporting under E2A and from IRB/IEC communication. One route does not automatically satisfy every other obligation.
Maintain the relevant awareness and transmission dates, acknowledgement, questions and follow-up. A sent email without evidence that it reached the designated safety route may be inadequate. Conversely, an automatically generated receipt is not proof that every clinical issue was evaluated. Trace the process to the decision and action required, not merely a message count.
Suspension and resumption
An authority or ethics restriction may apply to a cohort, procedure, recruitment or the whole trial. Establish its scope accurately. Involve the investigator for care of existing participants, the sponsor for wider actions and responsible functions for required notifications. Do not assume that every suspension means abruptly stopping all care, or that a sponsor email can override an authority restriction.
For resumption, verify the actual clearance and conditions, updated documents, relevant training and operational readiness. Preserve the record of what occurred during the restricted period. Backdating a new permission cannot authorise historical activity, and a note to file cannot remove a prior unauthorised exposure.
Completion and results
At completion or termination, the investigator provides relevant summaries/reports under the applicable process; the sponsor prepares trial reports and required communications. E6(R3) supports transparent reporting and informing participants about results and treatment when appropriate and available, respecting their preferences. The Declaration of Helsinki also addresses registration and making research results public, including negative and inconclusive findings.
A CRA contributes accurate site status, participant disposition, resolved or explained data issues and retrievable essential records. They should not infer that marketing approval automatically follows a completed trial, or that a clinical study report proves every record is complete. Reporting is the accountable presentation of the evidence, including meaningful limitations, deviations and quality issues.
Official sources
Checked October 18, 2026: ICH E6(R3), Principles and Annex 1 , ICH E8(R1) , ACRP CCRA Exam Content Outline .